

[View this email in your browser](#)



VALIDATING DIAGNOSTICS TO
COMBAT ANTIMICROBIAL RESISTANCE
BY OPTIMISING ANTIBIOTIC USE

 WWW.VALUE-DX.EU

NEWSLETTER NOVEMBER 2023

WAAW 2023 campaign



VALUE-Dx again joins the World Antibiotic Awareness Week initiative with a targeted campaign. This year we're highlighting the importance of appropriate antibiotic use for a better future with our annual cartoon. In addition, we created [a video](#) that dives deeper into this topic and explains how vital it is to preserve the power of antibiotics. [Discover our campaign here](#).


AMR expert interview with Dr. Agnes Sonnevend

Read our interview with Dr. Agnes Sonnevend from the Pécs University Hospital in Hungary. She discusses the current situation in her country and how this is being handled. Dr. Sonnevend emphasises the importance of tackling antimicrobial resistance, discusses AMR challenges and proposes actions on the level of health policy and science. [Read it here](#).




Progress and insights from the PRUDENCE & ADEQUATE trials

The PRUDENCE and ADEQUATE trials are pivotal initiatives addressing the escalating concern of antibiotic resistance. PRUDENCE focuses on a comprehensive point-of-care testing strategy for respiratory symptoms, considering patient recovery alongside antibiotic prescribing to offer insights into the effectiveness of a broader testing approach. It has recruited 86% of its 2500-participant goal, spanning primary and long-term care across multiple countries. The ADEQUATE trial, assessing antibiotic prescription practices in paediatric emergency departments, utilises randomization and the Biofire respiratory panel assay. Currently at 85% recruitment, the trial plans to reach its goal of 520 participants. [Continue reading](#).



Stakeholders' views and experiences on implementing new diagnostics in primary care



Have you read the insightful paper from our VALUE-Dx Social Science Team on stakeholders' views and experiences on implementing new diagnostics in primary care? It has been published in *Frontiers in Public Health* and is part of their World Antibiotic Awareness Week research topic. The team performed a qualitative study in the context of managing community-acquired acute respiratory tract infections. [Discover more here.](#)

VALUE-Dx annual meeting recap

In September 2023, the VALUE-Dx consortium convened in Barcelona for the General Assembly. It was a productive meeting where each work package provided comprehensive updates. The key discussions centred around the project's sustainability, health economic modelling, and target product profiles. The presentations on the PRUDENCE and ADEQUATE clinical trials delved into topics such as cost-effectiveness and process evaluation. [Read more.](#)



Copyright © 2022 VALUE-Dx, All rights reserved.



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited.

Our mailing address is:

value_dx@uantwerpen.be

Want to change how you receive these emails?

You can [update your preferences](#) or [unsubscribe from this list](#).

This email was sent to leandra.reijsmeijer@uantwerpen.be
[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)
Organisation · Universiteitsplein · Wilrijk 2160 · Belgium

